IL229258B - Amylin receptor agonists and pharmaceutical preparations containing them - Google Patents

Amylin receptor agonists and pharmaceutical preparations containing them

Info

Publication number
IL229258B
IL229258B IL22925813A IL22925813A IL229258B IL 229258 B IL229258 B IL 229258B IL 22925813 A IL22925813 A IL 22925813A IL 22925813 A IL22925813 A IL 22925813A IL 229258 B IL229258 B IL 229258B
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
receptor agonists
amylin receptor
amylin
agonists
Prior art date
Application number
IL22925813A
Other languages
English (en)
Hebrew (he)
Other versions
IL229258A0 (en
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL229258A0 publication Critical patent/IL229258A0/en
Publication of IL229258B publication Critical patent/IL229258B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
IL22925813A 2011-06-10 2013-11-05 Amylin receptor agonists and pharmaceutical preparations containing them IL229258B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11169405 2011-06-10
US201161496113P 2011-06-13 2011-06-13
PCT/EP2012/060900 WO2012168432A1 (en) 2011-06-10 2012-06-08 Polypeptides

Publications (2)

Publication Number Publication Date
IL229258A0 IL229258A0 (en) 2014-01-30
IL229258B true IL229258B (en) 2019-11-28

Family

ID=47295518

Family Applications (1)

Application Number Title Priority Date Filing Date
IL22925813A IL229258B (en) 2011-06-10 2013-11-05 Amylin receptor agonists and pharmaceutical preparations containing them

Country Status (18)

Country Link
US (4) US8722849B2 (https=)
EP (3) EP2718316B1 (https=)
JP (3) JP2014519509A (https=)
KR (1) KR102066987B1 (https=)
CN (3) CN103596972B (https=)
AU (1) AU2012266269B2 (https=)
BR (1) BR112013031268B1 (https=)
CA (1) CA2838884C (https=)
ES (1) ES2664509T3 (https=)
IL (1) IL229258B (https=)
MX (1) MX341324B (https=)
MY (1) MY161773A (https=)
PL (1) PL2718316T3 (https=)
RS (1) RS59977B1 (https=)
RU (1) RU2669999C2 (https=)
SI (1) SI2718316T1 (https=)
WO (3) WO2012168431A2 (https=)
ZA (1) ZA201309174B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168431A2 (en) * 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides
US8575091B1 (en) * 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
LT3004155T (lt) 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited Peptidų junginys
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
CN106687474A (zh) * 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
CA2971721A1 (en) 2014-12-23 2016-06-30 Colgate-Palmolive Company Oral care composition
CN105985995A (zh) * 2015-01-29 2016-10-05 暨南大学 一种利用家蚕生物反应器生产普兰林肽(pa)的方法
AR103954A1 (es) * 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
CN106554405B (zh) * 2015-09-30 2020-04-24 深圳翰宇药业股份有限公司 一种多肽及其用途、制备方法
CN106928086B (zh) * 2015-12-31 2019-05-31 深圳翰宇药业股份有限公司 一种长链化合物的制备方法
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
AR116632A1 (es) 2018-10-11 2021-05-26 Intarcia Therapeutics Inc Polipéptidos análogos de la amilina humana y sus métodos de uso
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
JP7505713B2 (ja) * 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
IL300620B2 (en) 2020-09-24 2025-12-01 Gubra As Ham15-52 analogues with improved amylin receptor (hamy3r) potency
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
US20250161471A1 (en) 2021-04-03 2025-05-22 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
WO2023110833A1 (en) 2021-12-13 2023-06-22 Novo Nordisk A/S Pharmaceutical formulations comprising a cyclodextrin
WO2023187067A1 (en) 2022-03-30 2023-10-05 Novo Nordisk A/S Formulation method
JP2025517031A (ja) * 2022-05-27 2025-05-30 ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド ヒトアミリン類似体、その誘導体およびその使用
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy
WO2024133739A1 (en) 2022-12-22 2024-06-27 Novo Nordisk A/S Amylin receptor agonists
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof
EP4727524A1 (en) 2023-06-15 2026-04-22 Novo Nordisk A/S Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin
TW202504913A (zh) 2023-06-21 2025-02-01 丹麥商西蘭製藥公司 減重
CN121358489A (zh) 2023-06-21 2026-01-16 西兰制药公司 具有改善特性的类似物
AU2024306538A1 (en) 2023-06-30 2025-12-04 Zealand Pharma A/S Combination therapy
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
WO2025160082A1 (en) * 2024-01-23 2025-07-31 Viking Therapeutics, Inc. Amylin analogs
WO2025168049A1 (zh) * 2024-02-07 2025-08-14 江苏恒瑞医药股份有限公司 胰岛淀粉样多肽类似物及其医药用途
EP4684802A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721760A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721761A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA936811B (en) * 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP1053001B1 (en) 1998-02-13 2010-12-15 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
AU3538799A (en) * 1998-04-30 1999-11-23 Kirin Brewery Company, Limited Human thrombopoietin mutants
US6890531B1 (en) * 1998-07-31 2005-05-10 Kirin Beer Kabushiki Kaisha Neuronal growth factor galectin-1
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7459527B2 (en) * 2004-03-31 2008-12-02 Xencor, Inc. BMP-7 variants with improved properties
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
RU2477286C2 (ru) * 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2009156473A1 (en) 2008-06-25 2009-12-30 Novo Nordisk A/S Derivatised hybrid peptides of amylin and salmon calcitonin
CN102197049B (zh) * 2008-10-21 2015-03-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
US8815541B2 (en) * 2009-11-25 2014-08-26 Novo Nordisk A/S Method for making polypeptides
WO2012168431A2 (en) * 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides

Also Published As

Publication number Publication date
ES2664509T3 (es) 2018-04-19
WO2012168430A3 (en) 2013-01-31
EP2718315B1 (en) 2017-12-27
MX341324B (es) 2016-08-16
WO2012168430A2 (en) 2012-12-13
US20140018286A1 (en) 2014-01-16
JP6121992B2 (ja) 2017-04-26
CN103596973A (zh) 2014-02-19
KR102066987B1 (ko) 2020-01-16
JP2014519511A (ja) 2014-08-14
CN103649115A (zh) 2014-03-19
EP2718315A2 (en) 2014-04-16
JP2014519509A (ja) 2014-08-14
CN103596972B (zh) 2018-03-20
US8741836B2 (en) 2014-06-03
BR112013031268A2 (pt) 2016-11-22
JP6247205B2 (ja) 2017-12-13
WO2012168432A1 (en) 2012-12-13
BR112013031268B1 (pt) 2020-05-12
CA2838884A1 (en) 2012-12-13
EP2718314A2 (en) 2014-04-16
CN103596972A (zh) 2014-02-19
MX2013013913A (es) 2013-12-16
WO2012168431A3 (en) 2013-01-31
AU2012266269A1 (en) 2013-11-21
EP2718316A1 (en) 2014-04-16
IL229258A0 (en) 2014-01-30
BR112013031268A8 (pt) 2018-01-16
RS59977B1 (sr) 2020-03-31
US20130059770A1 (en) 2013-03-07
WO2012168431A2 (en) 2012-12-13
SI2718316T1 (sl) 2020-03-31
US20130005646A1 (en) 2013-01-03
US9029325B2 (en) 2015-05-12
EP2718316B1 (en) 2019-12-04
AU2012266269B2 (en) 2017-04-06
ZA201309174B (en) 2022-08-31
MY161773A (en) 2017-05-15
JP2014519510A (ja) 2014-08-14
US8722849B2 (en) 2014-05-13
CN103649115B (zh) 2016-01-20
KR20140043764A (ko) 2014-04-10
RU2669999C2 (ru) 2018-10-17
US8575090B2 (en) 2013-11-05
CA2838884C (en) 2022-11-29
PL2718316T3 (pl) 2020-06-29
US20130012427A1 (en) 2013-01-10
RU2013156937A (ru) 2015-07-20

Similar Documents

Publication Publication Date Title
IL229258B (en) Amylin receptor agonists and pharmaceutical preparations containing them
AP3864A (en) Pharmaceutical composition
IL245326A0 (en) pharmaceutical preparation
PL2619182T3 (pl) Kompozycja farmaceutyczna
IL225457A0 (en) Pharmaceutical composition
GB201118232D0 (en) Pharmaceutical composition
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
ZA201308157B (en) Pharmaceutical composition
IL229677A0 (en) A liquid pharmaceutical preparation containing nitisinone
ZA201308152B (en) Pharmaceutical antiretroviral composition
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
HUE038538T2 (hu) Drotaverint tartalmazó gyógyszerészeti készítmény
IL221501A (en) Medicinal product containing miramistine
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
EP2665480A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THEM
HUP1100444A2 (en) Pharmaceutical composition
GB201001911D0 (en) Pharmaceutical composition
IL238629A0 (en) Antibodies against prokinectin receptor and their uses
ZA201308414B (en) Solid pharmaceutical composition
HUP1100445A2 (en) Pharmaceutical composition
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
GB201210831D0 (en) Pharmaceutical compositions and devices (F)
GB201019775D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed